Hydrogen Gas (H2)

Phase 1Small molecule

BBoston Children's Hospital

Hydrogen Gas (H2) is one of 44 small molecule programs targeting Encephalopathy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

EncephalopathyActive, not recruiting

EncephalopathyPhase 1

Active, not recruiting

Competition

Competitive Landscape

135 competitors in Encephalopathy

#DrugCompanyPhaseTrials

Xifaxan

SSalix

Phase 3

21 2

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

1 3

Alinia

RRomark Laboratories L.C.

Phase 3

4 4

PROCRIT

WWim Janssens

Phase 3

3 5

Cafcit

KKaken Pharmaceutical

Phase 3

1 6

Aranesp

Amgen

Phase 2

3 7

MS Contin

Merck & Co.

Phase 2

1 8

Yescarta

Gilead

Phase 2

1 9

Fludara

Sanofi

Phase 2

1 10

Fludara

Sanofi

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 1Not yet recruiting

Encephalopathy

NCT07411911

Clinical

Trials by Indication[1]

Encephalopathy1 trial

Hydrogen In Neonatal Encephalopathy (HIE) Trial

Not yet recruiting·—·Phase 1·NCT07411911·54 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Hydrogen Gas (H2). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hydrogen Gas (H2) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hydrogen Gas (H2). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Boston Children's Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBoston Children's Hospital

Hydrogen Gas (H2)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Encephalopathy1 trial

References

Drug Info

Quick Facts

Related News